Draft:AR-M 1000390
Submission declined on 23 May 2025 by Old-AgedKid (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
| ![]() |
Submission declined on 18 December 2024 by SafariScribe (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by SafariScribe 5 months ago.
| ![]() |
Comment: Same drug candidate already covered by ARM390. Merged relevant material from this draft into ARM390. Boghog (talk) 14:32, 23 May 2025 (UTC)
![]() | This article provides insufficient context for those unfamiliar with the subject.(December 2024) |
![]() | The topic of this draft may not meet Wikipedia's general notability guideline. |
![]() | |
Clinical data | |
---|---|
Other names | ARM-390 |
Identifiers | |
CAS Number |
|
ChemSpider | |
Chemical and physical data | |
Formula | C23H28N2O |
Molar mass | 348.490 g·mol−1 |
3D model (JSmol) | |
|
AR-M 1000390 (ARM-390) is a δ-opioid receptor agonist, known for its selectivity and potency in targeting the delta opioid receptor (DOR). It is a non-peptidic compound, derived from SNC 80, and has been studied for its potential analgesic effects without triggering acute desensitization of the receptor. AR-M 1000390 is a low-internalizing δ-opioid receptor agonist, meaning it does not induce rapid receptor desensitization. Studies suggest it may be brain-penetrant following systemic administration and has been investigated for its ability to reduce hyperalgesia in experimental models. The compound has been studied in preclinical trials for its potential in pain management and opioid receptor modulation. It has demonstrated high selectivity for the δ-opioid receptor, with an EC50 of 7.2±0.9 nM.[1][2][3]
Synthesis
[edit]
Weinreb ketone synthesis Ethyl isonipecotate [1126-09-6] (1) 1-Boc-4-(methoxy-methyl-carbamoyl)piperidine [139290-70-3] (2) N,N-diethyl-4-iodobenzamide [77350-52-8] (3) Tert-butyl 4-[4-(diethylcarbamoyl)benzoyl]piperidine-1-carboxylate, PC1057236 (4) Tert-butyl 4-[[4-(diethylcarbamoyl)phenyl]-hydroxy-phenylmethyl]piperidine-1-carboxylate, PC10814060 (5)
Dor Agonists
[edit]There are many DOR agonists that have been developed. For example, compare for: ADL5747, BW 373U86, JNJ-20788560, PN6047, SB 205607, SB-205588, SNC 121 & UFP-512.
References
[edit]- ^ Wei ZY, Brown W, Takasaki B, Plobeck N, Delorme D, Zhou F, Yang H, Jones P, Gawell L, Gagnon H, Schmidt R, Yue SY, Walpole C, Payza K, St-Onge S, Labarre M, Godbout C, Jakob A, Butterworth J, Kamassah A, Morin PE, Projean D, Ducharme J, Roberts E (October 2000). "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues". Journal of Medicinal Chemistry. 43 (21): 3895–905. doi:10.1021/jm000229p. PMID 11052794.
- ^ Marie N, Landemore G, Debout C, Jauzac P, Allouche S (August 2003). "Pharmacological characterization of AR-M1000390 at human delta opioid receptors". Life Sciences. 73 (13): 1691–704. doi:10.1016/s0024-3205(03)00489-2. PMID 12875901.
- ^ Pradhan AA, Walwyn W, Nozaki C, Filliol D, Erbs E, Matifas A, Evans C, Kieffer BL (December 2010). "Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward analgesic tolerance". The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 30 (49): 16459–68. doi:10.1523/JNEUROSCI.3748-10.2010. PMC 3086517. PMID 21147985.
- ^ Daniel Delorme, Edward Roberts, & Zhongyong Wei, WO1998028275 (AstraZeneca Canada Inc).